hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Supercritical drying Supercritical drying is reputed to be the most efficient drying technique but is rather expensive and difficult to implement. It was first implemented by Canham in 1994 and involves superheating the liquid pore above the critical point to avoid interfacial tension.
21CFR50.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 50--Protection of Human Subjects, Subpart A--General Provisions, Sec. 50.3 Definitions 21CFR312.3: Code of Federal Regulations, Title 21--Food and Drugs, Chapter I--Food and Drug Administration, Department of Health and Human Services, Part 312--Investigational New Drug Application, Subpart A--General Provisions, Sec. 312.3 Definitions and Interpretations, archived from the original on June 26, 2003 ICH E6: Guidance for Industry - E6 Good Clinical Practice: Consolidated Guidance (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, April 1996, archived from the original (PDF) on July 9, 2009 ICH E9: Guidance for Industry - E9 Statistical Principles for Clinical Trials (PDF), U.S. Department of Health and Human Services, Food and Drug Administration, September 1998, archived from the original (PDF) on July 10, 2009 NCI: Dictionary of Cancer Terms, National Cancer Institute, archived from the original on 2008-10-25, retrieved 2008-10-05 NLM: Glossary of Clinical Trials Terms, U.S. National Library of Medicine, archived from the original on 2011-09-02, retrieved 2008-10-05
The Pakistan–United States trade deal was concluded with a bilateral deal in Washington D.C. after intensive negotiations in July 2025, involving Pakistan's Finance Minister Muhammad Aurangzeb and Foreign Minister Ishaq Dar, alongside U.S. Trade Representative Jamieson Greer and Commerce Secretary Howard Lutnick. On 30–31 July 2025, President Donald Trump publicly confirmed the agreement via social media, calling it a "historic" energy partnership. Prime Minister Shehbaz Sharif hailed it as a "landmark deal" enhancing their enduring partnership.
Sources: en.wikipedia.org
Formation of the Quinonoid Intermediate PLP acts as an 'electron sink' absorbing delocalized electron density during the reaction intermediates (countering the excess electron density on the deprotonated a-carbon). PLP facilitates the enzyme activity, increasing the acidity of the alpha carbon by stabilizing the conjugate base. The PLP-stabilized carbanion intermediate formed is the quinonoid intermediate. Tyrosine and PLP stabilized 3C-Ring formation PLP and Tyrosine stabilize negative charges during deprotonation. Tyrosine attacks the sulfur bound carbon, allowing S(CH3)(Ado) to leave, and during ring formation, Tyrosine leaves. Note inhibitors AVG and AMA bind PLP to form a ketimine and oxime respectively (whose reverse reactions are much less favorable) and prevent the ACC synthase catalyzed reaction with SAM.
== Decay == Thorium-232 has a half-life of 14 billion years; it is itself an essentially pure alpha emitter with its first decay product radium-228. Radium-228 is itself unstable and leads to a decay chain known as the thorium series, which terminates at stable lead-208. The intermediates in the thorium-232 decay chain are all relatively short-lived; the longest-lived intermediate decay products are radium-228 and thorium-228, with half-lives of 5.75 years and 1.91 years, respectively. All others have half-lives under four days. The main decay branches are shown below:
Within the United States, the Patient Protection and Affordable Care Act of 2010 created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Researchers are optimistic that the introduction of biosimilars will reduce medical expenses to patients and the healthcare system.
The same day, Hitler met with Chamberlain and demanded the swift takeover of the Sudetenland by Nazi Germany under threat of war. Czechoslovakia, Hitler claimed, was slaughtering the Sudeten Germans. Chamberlain referred the demand to the British and French governments, both of which accepted. The Czechoslovak government resisted by arguing that Hitler's proposal would ruin the nation's economy and ultimately lead to German control of all of Czechoslovakia. The United Kingdom and France issued an ultimatum and made a French commitment to Czechoslovakia contingent upon its acceptance. On 21 September, Czechoslovakia capitulated. The next day, however, Hitler added new demands that insisted for the claims of Poland and Hungary to be satisfied as well. Romania was also invited to share in the division of Carpathian Ruthenia but refused because it was an ally of Czechoslovakia (see Little Entente). The Czechoslovak capitulation precipitated an outburst of national indignation. In demonstrations and rallies, Czechs and Slovaks called for a strong military government to defend the integrity of the state. A new cabinet, under General Jan Syrový, was installed, and on 23 September 1938, a decree of general mobilization was issued. The Czechoslovak Army was modern, had an excellent system of frontier fortifications and was prepared to fight. The Soviet Union announced its willingness to come to Czechoslovakia's assistance. Beneš, however, refused to go to war without the support of the Western powers.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.